Mass Spectrometry (MS) News and Research

RSS

Mapping peripheral blood glycoprotein profiles of COVID-19 patients

A team of researchers recently analyzed differential protein glyco-isoform distributions of symptomatic and asymptomatic coronavirus disease 2019 patients.

11 Jan 2022

Glycosylation and disulfide bonding profile of SARS-CoV-2 spike glycoprotein

Researchers found that virus-like particles produced by co-expression of SARS-CoV-2 S, membrane, envelope, and nucleocapsid proteins contain S glycoproteins, which are modified by complex carbohydrates.

29 Nov 2021

Functions of glycosylation in SARS-CoV-2 proteins and human receptor ACE2

In a review published in Signal Transduction and Targeted Therapy, researchers from Sichuan University have reviewed the available literature.

19 Nov 2021

Targeted proteomics for detection of SARS-CoV-2 proteins in clinical samples

A team of researchers from various institutions within the Netherlands examined the use of targeted MS-based proteomics for the detection of SARS-CoV-2 in research and clinical samples.

16 Nov 2021

Waters and Sartorius partner to help bioprocess scientists accelerate clone selection and process development

Waters Corporation and Sartorius announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.

From Sartorius 3 Nov 2021

Chlorophyll catabolite pheophorbide A shows potential against SARS-CoV-2

A new study identifies a potent SARS-CoV-2 antiviral, Pheophorbide a (PheoA), which is a compound derived from the plant Marchantia polymorpha L.

27 Oct 2021

Antibody validation and rapid peptide mapping technology

In this interview, News-Medical speaks to Bin Ma, President of Rapid Novor, about antibody validation and rapid peptide mapping technology.

From Rapid Novor Inc 11 Oct 2021

Studies shed light on the versatility, precision, and sensitivity of quantitative analytical tools

Three independent studies in the Journal of Pharmaceutical Analysis explore the potential uses and applications of quantitative analytical tools in the characterization and quality assessment of biological and medicinal compounds.

19 Aug 2021

Mass spectrometry used to develop N-glycosylation profiles for SARS-CoV-2 D614G

A new study has characterized and compared the N-glycosylation of the wild type (S-614D) and variant (S-614G) of SARS-CoV-2 S glycoproteins using MS techniques.

28 Jul 2021

Researchers use mass spectrometry to study immunogenic SARS-CoV-2 epitopes

A new study has been published on the bioRxiv* preprint server, which has used MS to identify T cell epitopes of SARS-CoV-2 conserved protein, i.e., the membrane glycol protein (MGP) and the non-structure protein-13 (NSP13).

23 Jul 2021

Can saliva metabolomics predict COVID-19 severity?

New research suggests that saliva metabolomics may be able to help prognosticate disease severity in COVID-19 positive individuals.

9 Jul 2021

Bruker’s molecular phenomics research tools enable new insights into ‘long COVID’ and post-acute metabolic abnormalities

A clinical research collaboration on COVID-19 pheno-conversion and subsequent pheno-reversion has discovered transient and persistent systemic changes of the molecular signatures in patient blood samples three months after the acute COVID-19 disease phase.

From Bruker BioSpin Division 22 Jun 2021

Analytical Mass Spectrometry: How Did We Get Here, Where are We Going?

News-Medical interviews Rick Yost, winner of the Pittsburgh Analytical Chemistry Award 2021, about his research into mass spectrometry.

From Pittcon 3 Mar 2021

Novel gel electrophoresis method for MS-based quantification of protein biomarkers

Mass spectrometry (MS) is a powerful method for biomarker analysis because it enables highly sensitive and accurate measurement of target molecules in clinical samples.

18 Feb 2021

Researchers develop detailed map of protein-protein interactions between SARS-CoV-2 and the host

By conducting a state-of-the-art interactome study between SARS-CoV-2 and host cells, researchers from the University of Texas MD Anderson Cancer Center in Houston identified 437 human proteins as the high-confidence interacting proteins – with substantial implications for understanding coronavirus disease 2019 (COVID-19) pathology and potential treatments.

5 Jan 2021